welcome to LeanBio
Pioneering Small Molecule Solutions for Obesity Treatment
LeanBio is a small agile drug discovery company, which exploits enhanced chemistry to discover and optimize small molecule medicines for obesity and immunology targets. We leverage known validated targets treated with biologics to address the need for chronic oral treatment of patients with obesity and immunological disorders.
Innovative Biotech for Metabolic Health
The future of obesity treatment is oral, effective, and accessible
At LeanBio, we develop next-generation small-molecule drugs for obesity—built on validated biology, advanced AI, and an agile development model. We focus solely on proven targets such as GIP and Amylin, aiming to provide safe, tolerable, and practical alternatives to injectable therapies. When lead programs advance to Lead optimization, we expand into immunology. Backed by a highly experienced team and front-line innovation partners, we’re delivering scalable solutions with strong clinical and commercial potential. The future starts here!
Innovative Biotech for Sustained Health
That's why you should choose us
At LeanBio.dk, we combine scientific excellence, agility, and deep industry insight to deliver innovative solutions in obesity treatment. Our focused expertise in small molecule drug development, paired with a highly experienced team and a commitment to validated science, ensures that every step we take is aimed at real, impactful results. Whether you’re a partner, investor, or collaborator, choosing us means choosing a shared vision for better health outcomes in most productive ways.
Focused Expertise
We specialize in obesity-focused therapeutics, ensuring deep understanding and targeted innovation.
Agile and Responsive
As a small, nimble company, we adapt quickly to new data, opportunities, and challenges. Lean is faster than big.
Experienced Team
Our scientists and drug developers all bring decades of hands-on experience in pharmaceutical R&D.
are you interested?
Do you want to hear more?
Let’s connect. Whether you’re looking to collaborate, invest, or explore how our approach to small molecule obesity treatment can create real-world impact, we’re ready to share our vision and progress with you.